Baumann Kreuziger Lisa M, Datta Yvonne H, Johnson Andrew D, Zantek Nicole D, Shanley Ryan, Reding Mark T
aDivision of Hematology, Oncology, and Transplantation, University of Minnesota bDepartment of Laboratory Medicine and Pathology, University of Minnesota cCTSI Biostatstics, University of Minnesota, Minneapolis, Minnesota, USA.
Blood Coagul Fibrinolysis. 2014 Apr;25(3):232-6. doi: 10.1097/MBC.0000000000000030.
The international normalized ratio (INR) can be unreliable in patients with lupus anticoagulants (LACs) or other conditions affecting baseline testing. Alternative methods to assess anticoagulation on warfarin through measures of vitamin K-dependent factor activity by clot based or chromogenic assays may be necessary. In this patient population, the ideal method is unknown. Thirty-six patients stable on warfarin with LAC or unreliable INR testing had an INR, a prothrombin time-based clotting assay for factor II (FII) activity, and a chromogenic assay for factor X (CFX) activity were performed simultaneously. Eighty-nine sets of measurements were obtained of which 83 sets included all three assays. CFX and FII levels were well correlated (r = 0.92) in all patients and in 26 patients with a documented antiphospholipid antibody (r = 0.93). Parallel testing was seen in 99% of FII assays. Sixty-one percent of CFX and 57% of FII were within the therapeutic range. In 32 CFX and FII pairs wherein assessment of anticoagulation was discordant, 16 CFX agreed with INR and 13 FII agreed with INR (McNemar's, χ = 0.14, P = 0.7). The number of times tests were discrepant was not statistically different between CFX and FII (P = 0.36). CFX and FII activity are well correlated in patients that require alternative monitoring of warfarin. Either test can be used in this population.
国际标准化比值(INR)在患有狼疮抗凝物(LAC)或其他影响基线检测的疾病的患者中可能不可靠。通过基于凝血或显色测定法测量维生素K依赖因子活性来评估华法林抗凝效果的替代方法可能是必要的。在这一患者群体中,理想的方法尚不清楚。36名服用华法林病情稳定但伴有LAC或INR检测不可靠的患者同时进行了INR、基于凝血酶原时间的因子II(FII)活性凝血测定以及因子X(CFX)活性显色测定。共获得89组测量值,其中83组包含所有三项检测。在所有患者以及26名有抗磷脂抗体记录的患者中,CFX和FII水平相关性良好(r = 0.92和r = 0.93)。99%的FII检测呈平行关系。61%的CFX和57%的FII处于治疗范围内。在32对CFX和FII检测结果不一致的抗凝评估中,16个CFX结果与INR一致,13个FII结果与INR一致(麦克尼马尔检验,χ = 0.14,P = 0.7)。CFX和FII检测结果出现差异的次数在统计学上无显著差异(P = 0.36)。在需要对华法林进行替代监测的患者中,CFX和FII活性相关性良好。这两种检测方法均可用于该患者群体。